Pfizer announced that Trumenba (meningococcal group B vaccine) is now available for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in patients aged 10–25 years. Trumenba is the first vaccine to prevent meningococcal disease caused by the specific serogroup B.
The vaccine suspension is composed of two recombinant LP2086 antigens, or factor H binding proteins (fHBP). Antigens from both types of fHBP, subfamily A and subfamily B have been included in the vaccine. Protection against invasive meningococcal disease is conferred mainly by complement-mediated antibody-dependent killing of N. meningitidis.
Shipments to retail pharmacies, hospitals, physicians’ offices, college health centers, and other medical practices are currently available to order. Trumenba vaccine is available as 0.5mL single-use prefilled syringes in 5- and 10-count packages.
For more information call (800) 666-7248 or visit Trumenba.com.